[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504505":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":72,"collaborators":20,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":20,"enrollmentInfo":86,"targetDuration":20,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open Arm","EXPERIMENTAL","All patients will receive cyclophosphamide on Day +3 and Day +4 following transplant.",[13],"Drug: Cyclophosphamide",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Cyclophosphamide","Cyclophosphamide will be administered at 50, 40, 32, or 25 mg\u002Fk\u002Fd intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Ronald Paquette, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Clinical Trials Navigator","CONTACT","310-423-3713","GroupCancerTrialInformation@cshs.org",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Los Angeles","California","90048","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-118.24368,34.05223,{"lat":43,"lon":42},[46,49,52,54,56,58,60,62,64,66,68,70],{"name":47,"role":28,"phone":48,"phoneExt":20,"email":30},"Clinical Trial Recruitment Navigator","13104232133",{"name":50,"role":51,"phone":20,"phoneExt":20,"email":20},"John Chute, MD","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":20,"phoneExt":20,"email":20},"Justin Darrah, MD",{"name":55,"role":51,"phone":20,"phoneExt":20,"email":20},"Akil Merchant, MD",{"name":57,"role":51,"phone":20,"phoneExt":20,"email":20},"Noah Merin, MD, PhD",{"name":59,"role":51,"phone":20,"phoneExt":20,"email":20},"Joshua Sasine, MD, PhD",{"name":61,"role":51,"phone":20,"phoneExt":20,"email":20},"Robert Vescio, MD",{"name":63,"role":51,"phone":20,"phoneExt":20,"email":20},"Arash Asher, MD",{"name":65,"role":51,"phone":20,"phoneExt":20,"email":20},"Philip Chang, MD",{"name":67,"role":51,"phone":20,"phoneExt":20,"email":20},"Alan Kwan, MD",{"name":69,"role":51,"phone":20,"phoneExt":20,"email":20},"Stephen Shiao, MD, PhD",{"name":71,"role":51,"phone":20,"phoneExt":20,"email":20},"Hannah Lee, MD",{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Ronald Paquette","Medical Director, Blood and Marrow Transplant Program","100504505","phase-1-post-transplant-cyclophosphamide-in-patients-aged--65-years-undergoing-haploidentical-transplant-100504505",false,"NCT05849207","Post-Transplant Cyclophosphamide in Patients Aged >\u002F= 65 Years Undergoing Haploidentical Transplant","IIT2022-03-Paquette-GeriBMT: A Phase I Study of De-Escalation of Post-Transplant Cyclophosphamide Dosing in Patients Aged >\u002F= 65 Years Undergoing Conditioning With Fludarabine and Total Body Irradiation 800 cGy","GeriBMT","Inclusion Criteria:\n\n* Patient age \\>\u002F= 65 years\n* Patient and related Donor (if applicable) sign the Informed Consent Form for the study. If donor is unrelated, donor does not sign Informed Consent Form and this will not affect recipient study eligibility.\n* Patient meets standard criteria for allogeneic stem cell transplant\n* Patient is deemed suitable to receive Flu\u002FTBI 800 conditioning regimen as standard of care transplant\n* Donor is willing to donate peripheral blood stem cells\n\nExclusion Criteria:\n\n* Patient has a diagnosis of myelofibrosis\n* Patient has high titer antibodies (\\>10,000 mean fluorescent intensity) against one or more donor HLA antigens\n* Patient has undergone prior autologous or allogeneic stem cell transplant\n* Requiring sedation for cardiac MRIs.\n* Prohibited Implants and\u002For Devices:\n\n  * Mechanical, magnetic or electrical activated implants (i.e. cardiac pacemakers, neurostimulators and infusion pumps)\n  * Ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged.\n* Subjects with claustrophobia, problems being in enclosed spaces, or inability to lie supine.","ALL","65 Years",{"count":87,"type":88},26,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \\>\u002F= 65 years with hematologic malignancies.",[94],"Hematologic Malignancies",[96],"Allogeneic Transplantation","2026-05-01",{"date":99,"type":100},"2026-05-07","ACTUAL",{"date":102,"type":100},"2023-10-24",{"date":104,"type":88},"2028-07-01",{"name":74,"class":6},1]